An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

NCT03952039 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Post-Polycythemia Vera
Myelofibrosis

Interventions

DRUG: FEDRATINIB
DRUG: Best Available Therapy (BAT)

Sponsor

Celgene

Collaborators

[object Object]